Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Drug

CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops

Fineline Cube Sep 9, 2026
Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Deals

Science Sun Pharma and Mabworks Biotech Sign Strategic Cooperation Pact

Fineline Cube Jul 11, 2022

Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with...

Company Deals

Hangzhou DAC Bio Partners with Janssen on ADC Development Deal

Fineline Cube Jul 11, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...

Policy / Regulatory

NHSA Sets 2022 Goals for Basic Medical Insurance Funding and Reforms

Fineline Cube Jul 8, 2022

The National Healthcare Security Administration (NHSA), Ministry of Finance (MOF), and State Taxation Administration (STA)...

Company Drug

Neurophth’s NR082 Gene Therapy Receives BTD for Leber Hereditary Optic Neuropathy

Fineline Cube Jul 8, 2022

China’s Center for Drug Evaluation (CDE) has awarded breakthrough therapy designation (BTD) to Wuhan Neurophth...

Company Drug

Biotheus Inc.’s PM1009 Bispecific Antibody Enters Clinical Trial Review for Solid Tumors

Fineline Cube Jul 8, 2022

China-based Biotheus Inc. announced that its clinical trial filing for PM1009, a bispecific antibody (BsAb)...

Company Deals

Rainmed Medical Makes IPO Debut on Hong Kong Exchange with Valuation Over USD 764M

Fineline Cube Jul 8, 2022

Suzhou Rainmed Medical Technology Co., Ltd, a China-based vascular intervention robot manufacturer, has completed its...

Company Deals

MicuRx Pharmaceuticals Approved for STAR Market IPO by CSRC

Fineline Cube Jul 8, 2022

The China Securities Regulatory Commission (CSRC) has approved the initial public offering (IPO) of Sino-US...

Company Drug

Innovent Biologics’ Pemazyre Becomes First FGFR2 Inhibitor Approved in China

Fineline Cube Jul 8, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced that the first prescription has been filled in...

Company Drug

Dizal Pharma’s DZD1516 Receives NMPA Green Light for HER2+ Breast Cancer Trial

Fineline Cube Jul 8, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192), spun out from AstraZeneca’s China drug discovery unit...

Company Deals

WuXi XDC Partners with AbTis to Advance ADC Development and Manufacturing

Fineline Cube Jul 8, 2022

WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (SHA: 603259),...

Company Drug

GenScript Biotech’s Legend Biotech Terminates LB1901 CAR-T Phase I Trial

Fineline Cube Jul 8, 2022

Hong Kong-based GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ:...

Company Deals Digital

ClouDr Group’s Hong Kong IPO Nets HKD 482 Million with Sanofi as Investor

Fineline Cube Jul 7, 2022

Hangzhou-based ClouDr Group Ltd (HKG: 9955), a one-stop chronic disease management and smart medical platform,...

Company Deals

Baifu Laser Raises RMB 100 Million in Series A Funding for Optoelectronic Equipment

Fineline Cube Jul 7, 2022

China-based Nanjing Baifu Laser Technology Co., Ltd reportedly raised close to RMB 100 million (USD...

Company Medical Device

Oriomics Launches XiaoWeiAn Multi-Tumor Early Screening Product

Fineline Cube Jul 7, 2022

Hangzhou Ao’rui Biological Technology Co., Ltd (Oriomics) announced the market launch of XiaoWeiAn, a multi-tumor...

Company Drug

Zhaoke Ophthalmology Enrolls First Patient in TAB014 Phase III Study for wAMD

Fineline Cube Jul 7, 2022

Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...

Company Deals

GeneRulor Medical Technology Raises Funds for Gene Editing Diagnostics

Fineline Cube Jul 7, 2022

China-based gene editing specialist ZhuHai GeneRulor Medical Technology Co., Ltd. reportedly raised “tens of millions”...

Company Drug

Brii Biosciences Launches Anti-COVID-19 Antibody Cocktail in China

Fineline Cube Jul 7, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced the commercial launch in China of the anti-COVID-19...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Under FDA Review for NPC Treatment

Fineline Cube Jul 7, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the Biologics License Application (BLA) for...

Company Deals

I-Mab and MorphoSys License Drugs to HIBio in Global Oncology Deal

Fineline Cube Jul 7, 2022

China-based I-Mab (NASDAQ: IMAB) detailed a licensing and equity investment deal between its German partner...

Company Deals

Adicon Holdings and Guardant Health Partner on Genomic Profiling in China

Fineline Cube Jul 7, 2022

China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ:...

Posts pagination

1 … 704 705 706 … 718

Recent updates

  • CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops
  • Gilead Opens Foster City Research Center for Oncology and Inflammation
  • Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data
  • China Launches Five-Year Plan to Expand High-Quality Eye Health Services
  • Ascletis Starts US Phase 1 Trial of Oral ASC36 for Obesity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops

Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Company Drug

Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data

Policy / Regulatory

China Launches Five-Year Plan to Expand High-Quality Eye Health Services

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.